|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIGH |
Gene summary for PIGH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIGH | Gene ID | 5283 |
| Gene name | phosphatidylinositol glycan anchor biosynthesis class H | |
| Gene Alias | GPI-H | |
| Cytomap | 14q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q14442 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5283 | PIGH | LZE4T | Human | Esophagus | ESCC | 1.10e-10 | 2.44e-01 | 0.0811 |
| 5283 | PIGH | LZE8T | Human | Esophagus | ESCC | 4.62e-05 | 1.40e-01 | 0.067 |
| 5283 | PIGH | LZE20T | Human | Esophagus | ESCC | 2.40e-06 | 1.78e-01 | 0.0662 |
| 5283 | PIGH | LZE22T | Human | Esophagus | ESCC | 8.67e-05 | 4.32e-01 | 0.068 |
| 5283 | PIGH | LZE24T | Human | Esophagus | ESCC | 8.77e-19 | 5.77e-01 | 0.0596 |
| 5283 | PIGH | LZE6T | Human | Esophagus | ESCC | 5.75e-03 | 1.21e-01 | 0.0845 |
| 5283 | PIGH | P1T-E | Human | Esophagus | ESCC | 7.83e-05 | 1.77e-01 | 0.0875 |
| 5283 | PIGH | P2T-E | Human | Esophagus | ESCC | 6.68e-26 | 3.87e-01 | 0.1177 |
| 5283 | PIGH | P4T-E | Human | Esophagus | ESCC | 1.93e-25 | 5.32e-01 | 0.1323 |
| 5283 | PIGH | P5T-E | Human | Esophagus | ESCC | 2.29e-14 | 1.45e-01 | 0.1327 |
| 5283 | PIGH | P8T-E | Human | Esophagus | ESCC | 3.60e-28 | 4.49e-01 | 0.0889 |
| 5283 | PIGH | P9T-E | Human | Esophagus | ESCC | 1.37e-08 | 2.61e-01 | 0.1131 |
| 5283 | PIGH | P10T-E | Human | Esophagus | ESCC | 3.35e-46 | 7.86e-01 | 0.116 |
| 5283 | PIGH | P11T-E | Human | Esophagus | ESCC | 2.60e-06 | 2.66e-01 | 0.1426 |
| 5283 | PIGH | P12T-E | Human | Esophagus | ESCC | 8.92e-49 | 7.99e-01 | 0.1122 |
| 5283 | PIGH | P15T-E | Human | Esophagus | ESCC | 1.63e-54 | 1.05e+00 | 0.1149 |
| 5283 | PIGH | P16T-E | Human | Esophagus | ESCC | 1.37e-30 | 5.94e-01 | 0.1153 |
| 5283 | PIGH | P17T-E | Human | Esophagus | ESCC | 2.41e-06 | 3.04e-01 | 0.1278 |
| 5283 | PIGH | P19T-E | Human | Esophagus | ESCC | 1.56e-04 | 5.66e-01 | 0.1662 |
| 5283 | PIGH | P20T-E | Human | Esophagus | ESCC | 7.61e-24 | 5.21e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00421571 | Liver | HCC | lipoprotein metabolic process | 86/7958 | 135/18723 | 5.21e-07 | 8.38e-06 | 86 |
| GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
| GO:00066431 | Liver | HCC | membrane lipid metabolic process | 115/7958 | 203/18723 | 3.17e-05 | 3.22e-04 | 115 |
| GO:00421581 | Liver | HCC | lipoprotein biosynthetic process | 58/7958 | 96/18723 | 2.99e-04 | 2.13e-03 | 58 |
| GO:00064971 | Liver | HCC | protein lipidation | 55/7958 | 92/18723 | 6.12e-04 | 3.82e-03 | 55 |
| GO:0046467 | Liver | HCC | membrane lipid biosynthetic process | 78/7958 | 142/18723 | 1.85e-03 | 9.46e-03 | 78 |
| GO:0006664 | Liver | HCC | glycolipid metabolic process | 57/7958 | 100/18723 | 2.40e-03 | 1.17e-02 | 57 |
| GO:0006506 | Liver | HCC | GPI anchor biosynthetic process | 22/7958 | 32/18723 | 2.43e-03 | 1.18e-02 | 22 |
| GO:1903509 | Liver | HCC | liposaccharide metabolic process | 57/7958 | 101/18723 | 3.25e-03 | 1.49e-02 | 57 |
| GO:0006505 | Liver | HCC | GPI anchor metabolic process | 22/7958 | 33/18723 | 4.38e-03 | 1.90e-02 | 22 |
| GO:0006661 | Liver | HCC | phosphatidylinositol biosynthetic process | 69/7958 | 131/18723 | 1.19e-02 | 4.35e-02 | 69 |
| GO:00066432 | Oral cavity | OSCC | membrane lipid metabolic process | 111/7305 | 203/18723 | 4.02e-06 | 4.69e-05 | 111 |
| GO:00421572 | Oral cavity | OSCC | lipoprotein metabolic process | 77/7305 | 135/18723 | 1.61e-05 | 1.60e-04 | 77 |
| GO:00064972 | Oral cavity | OSCC | protein lipidation | 56/7305 | 92/18723 | 1.77e-05 | 1.72e-04 | 56 |
| GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
| GO:00421582 | Oral cavity | OSCC | lipoprotein biosynthetic process | 57/7305 | 96/18723 | 4.17e-05 | 3.61e-04 | 57 |
| GO:00464672 | Oral cavity | OSCC | membrane lipid biosynthetic process | 77/7305 | 142/18723 | 1.63e-04 | 1.13e-03 | 77 |
| GO:00065062 | Oral cavity | OSCC | GPI anchor biosynthetic process | 21/7305 | 32/18723 | 2.08e-03 | 9.59e-03 | 21 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005632 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa0056311 | Esophagus | ESCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 21/4205 | 26/8465 | 1.10e-03 | 3.42e-03 | 1.75e-03 | 21 |
| hsa00563 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| hsa005631 | Liver | HCC | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 18/4020 | 26/8465 | 2.08e-02 | 4.81e-02 | 2.68e-02 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIGH | deletion | Frame_Shift_Del | novel | c.1delN | p.Met1? | p.M1? | Q14442 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| PIGH | SNV | Missense_Mutation | novel | c.7G>T | p.Asp3Tyr | p.D3Y | Q14442 | protein_coding | deleterious_low_confidence(0) | benign(0.165) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PIGH | SNV | Missense_Mutation | rs781639045 | c.115N>T | p.Arg39Cys | p.R39C | Q14442 | protein_coding | tolerated(0.06) | benign(0) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PIGH | SNV | Missense_Mutation | c.308N>T | p.Ser103Phe | p.S103F | Q14442 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIGH | SNV | Missense_Mutation | c.203C>T | p.Ala68Val | p.A68V | Q14442 | protein_coding | tolerated(0.22) | benign(0.051) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIGH | SNV | Missense_Mutation | c.185G>T | p.Ser62Ile | p.S62I | Q14442 | protein_coding | tolerated(0.12) | benign(0.235) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PIGH | SNV | Missense_Mutation | c.474G>T | p.Gln158His | p.Q158H | Q14442 | protein_coding | deleterious(0.01) | possibly_damaging(0.549) | TCGA-B5-A0JZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
| PIGH | SNV | Missense_Mutation | c.367N>A | p.Val123Ile | p.V123I | Q14442 | protein_coding | tolerated(0.08) | benign(0.017) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PIGH | SNV | Missense_Mutation | c.252G>T | p.Lys84Asn | p.K84N | Q14442 | protein_coding | deleterious(0.01) | benign(0.242) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIGH | SNV | Missense_Mutation | novel | c.46N>A | p.Ala16Thr | p.A16T | Q14442 | protein_coding | tolerated(0.34) | benign(0.007) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |